Welcome to AusBio

Aus Bio Ltd. is a public but unlisted, Melbourne based biotechnology research and development company (R&D). Principal objectives are:

1. Development of an innovative research program to create new therapeutic products for specific disease states eg influenza.
2. Create significant scientific and commercial alliances.
3. Increase shareholder value.

2021 AGM Results

Results of the Annual General Meeting held on Thursday, 18th November 2021.

Notice of Annual General Meeting 2021

The Annual General Meeting will be held as a Virtual Meeting, on Thursday, 18th November 2021 at 11:00am.

2021 AGM Virtual Meeting

Instructions to log into the 2021 AGM Virtual Meeting.

Chairman's Letter to Shareholders

Link Market Services Ltd has been engaged to provide Virtual Meeting Services to Aus Bio Limited.

2021 Annual Report and Financial Statements

Full signed financial statements (financial year 2021).

2021 Operational Review

On behalf of your Board we are pleased to present the 2021 Review of Operations and Corporate Governance Statement.

AusVir Press Release

Melbourne, Australia; 5 March 2020.
A newly formed biopharmaceutical company AusVir Therapeutics Pty Ltd, focused on the development and commercialization of novel medicines targeting viral infection, today announced that it has raised AUD$23 million in a Series A financing led by Morningside Venture Investments.

Aus Bio in Bloomberg

“New Drugs are Coming to Fight Nasty Flu Seasons”

Influenza

Aus Bio’s MD2009 project has resulted in the pre-clinical development of a number of antiviral drug candidates which have a different mode of action to the currently used neuraminidase inhibitors.

Respiratory

Aus Bio’s Respiratory Project – MD990 – has resulted from the identification of several specific carbohydrates, which have been shown to influence and enhance recovery of injured human respiratory cells.